Kudela M, Pilka R, Lubuský M, Hejtmánek P, Dzubák P, Brychtová S
Porodnicko-gynekologická klinika LF UP a FN Olomouc.
Ceska Gynekol. 2011 Jun;76(3):194-9.
The aim of the study was the analysis of the new molecular genetic immunomarkers (p53, c-erbB-2, Ki 67, bcl-2) hormonal receptors (ER, PR) and ploidy disturbances and their relation to the most important prognostic factors for endometrial cancer.
Prospective study.
Dept. of Gynaecology and Obsterics, Laboratory of Experimental Medicine, Institute of Pathology, Institute of Molecular and Transplational Medicine, Medical Faculty and University Hospital, Olomouc.
The study group consisted of 88 endometrial cancer patients. The biopsies of the tumours obtained at operations were routinely histopathologically examined. Subsequently, the immunohistochemical tumormarkers were determined. The same biopsies were examined by microdissection and flow cytometric ploidy analysis and karyotyping. The findings were compared with the most important prognostic factors for endometrial cancer, mainly with clinical stage of the disease, grade and histopathological type.
Aneuploidy was found in 71% in the group of poorly differentiated endometrial cancers (G3) in contrast to 47% in the group of G1 and G2 tumours. High expression of p53, Ki 67, c-erbB-2 and low rate of sex hormone receptors was found in the prognostically unfavourable group (G3).
Aneuploidy seems to be an important prognostical factor for endometrial cancer patients. Identification of p53, Ki 67, c-erbB-2, ER a PR is a useful tool to specify a group of prognostically unfavourable patients.
本研究旨在分析新的分子遗传免疫标志物（p53、c-erbB-2、Ki 67、bcl-2）、激素受体（ER、PR）及倍体紊乱情况，及其与子宫内膜癌最重要的预后因素之间的关系。
前瞻性研究。
奥洛穆茨医科大学医学院及大学医院妇产科、实验医学实验室、病理学研究所、分子与转化医学研究所。
研究组由88例子宫内膜癌患者组成。对手术中获取的肿瘤活检组织进行常规组织病理学检查。随后，测定免疫组化肿瘤标志物。对相同的活检组织进行显微切割及流式细胞术倍体分析和核型分析。将研究结果与子宫内膜癌最重要的预后因素进行比较，主要是疾病的临床分期、分级和组织病理学类型。
在高分化子宫内膜癌（G3）组中，71%发现非整倍体，而在G1和G2肿瘤组中这一比例为47%。在预后不良组（G3）中发现p53、Ki 67、c-erbB-2高表达以及性激素受体低表达。
非整倍体似乎是子宫内膜癌患者的一个重要预后因素。识别p53、Ki 67、c-erbB-2、ER和PR是确定一组预后不良患者的有用工具。
